Education
About Us
Working with TipRanks
Follow Us
Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥361.00 - ¥749.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥24.41B
Enterprise Value¥21.07B
Total Cash (Recent Filing)¥3.92B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.19
Price to Sales (P/S)7.56
P/FCF Ratio-82.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNear-zero debt provides durable financial flexibility, lowering refinancing and interest-rate risk and enabling the firm to fund development and manufacturing needs from equity or cash. This structural strength supports operations through R&D cycles and clinical timelines over months to years.
Accelerating Revenue GrowthStrong sequential top-line acceleration implies growing commercial adoption of products and CDMO services, which can drive scale benefits and improve long-term unit economics. If sustained, this trend supports reinvestment in manufacturing and broader market penetration.
High Gross MarginsSustained gross margins above 50% indicate durable product-level pricing power and favorable unit economics for cell-based products. This provides scope for operating leverage as revenue scales, assuming SG&A and R&D growth are controlled, improving long-term profitability potential.
Bears Say
Weak Cash GenerationRecurrent negative operating and free cash flows mean the business cannot reliably self-fund growth and development, increasing reliance on external capital. Over 2–6 months this elevates dilution and financing risk and constrains investments in capacity or trials.
Profitability VolatilitySwinging from modest profits to material losses signals inconsistent control of operating costs or lumpy revenues. This undermines predictability for reinvestment, budgeting and stakeholder confidence, and suggests underlying cost structure or commercialization execution issues.
Negative Return On EquityA shift to negative ROE shows the firm is not currently converting equity capital into returns, reducing long-term capital efficiency. Persistent negative ROE pressures the need for strategic change or additional financing and weakens the case for equity-holders over time.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥361.00 and its highest was ¥749.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥24.41B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is May 01, 2026 which is in 73 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on Jan 30, 2026. The company reported -¥4.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.56.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.